Temporal arteritis, formally known as giant cell arteritis (GCA), is not curable in the way an infection can be cleared with antibiotics. It is an autoimmune condition, and autoimmune conditions are managed rather than eradicated. That said, roughly half of patients with biopsy-proven GCA do reach long-term remission, meaning they eventually stop all medication and stay symptom-free for years. The gap between “cure” and “lasting remission” matters, because even patients who have been off treatment for a long time can relapse, and the disease carries serious risks to vision and the aorta that demand respect even when things seem quiet.
Why GCA Cannot Be Permanently Eliminated
The underlying problem in GCA is an immune system that has turned against the walls of certain arteries. Specialized immune cells in the artery wall, particularly a type of sentinel cell embedded in the outer layer of medium-sized arteries, begin recruiting inflammatory T cells into the vessel wall. Those T cells multiply there and drive macrophages to cause damage, thickening the artery lining and choking off blood flow. Multiple branches of the immune system are involved: one wave of inflammation dominates the early, acute phase, while a different, slower-burning type sustains chronic vessel-wall damage over time.1PubMed Central. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications
The sentinel cells that kick off this process appear to be a normal part of artery architecture. They sit at the border between the outer and middle layers of the vessel in healthy people, but in GCA they get activated and begin pumping out signals that attract more immune cells.2PubMed. Vascular dendritic cells in giant cell arteritis Because these sentinel cells are a permanent feature of your blood vessels, the potential trigger for vasculitis never truly disappears. Treatment can suppress the inflammation and, in many cases, the immune system settles back down on its own over months to years. But there is no therapy that selectively removes or reprograms those sentinel cells, which is the fundamental reason a permanent cure remains out of reach.
Glucocorticoids Are Still the First-Line Treatment
When GCA is suspected, high-dose corticosteroids (usually prednisone) are started immediately, often before the diagnosis is formally confirmed. The urgency is not about comfort; it is about preventing irreversible vision loss. Steroids are strikingly effective at halting the inflammation within days, and they remain the foundation of GCA treatment.3PubMed Central. Giant cell arteritis: Current treatment and management When there is suspected eye involvement, treatment may start with intravenous steroids to act faster.4PubMed. The Treatment of Giant Cell Arteritis
The catch is that steroid therapy for GCA is not a short course. Most patients need to taper slowly over a year or more, and many need low doses for considerably longer. The side effects of long-term corticosteroid use are well known and cumulative: weight gain, bone thinning, elevated blood sugar, mood changes, thin skin, and susceptibility to infections. In GCA patients, who are almost always over 50 and often over 70, these side effects land on people who are already at elevated risk for osteoporosis, diabetes, and cardiovascular disease. The entire field of GCA treatment has essentially been shaped by the tension between needing steroids to control the disease and needing to get patients off steroids as quickly as safely possible.
Tocilizumab and Other Steroid-Sparing Options
Tocilizumab, a biologic drug that blocks a key inflammatory signaling molecule called IL-6, changed the treatment landscape for GCA. In the landmark GiACTA trial, tocilizumab proved highly effective at maintaining remission while allowing patients to taper off steroids much faster than they could with steroids alone.5The Open Rheumatology Journal. Steroid-Sparing Agents in Giant Cell Arteritis Real-world data has confirmed that pattern. In one comparison from two referral centers, about two-thirds of patients on tocilizumab achieved steroid-free remission by 12 months, compared with roughly one in nine on methotrexate.6PubMed Central. Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres A proof-of-concept study even suggested that 12 months of tocilizumab combined with just 8 weeks of prednisone could be enough to induce and maintain remission.7The Lancet Rheumatology. Outcomes of tocilizumab in combination with short-term prednisone in giant cell arteritis: a prospective, single-arm, proof-of-concept study
Methotrexate is the other commonly used steroid-sparing drug. It is far less expensive than tocilizumab and has decades of use in other inflammatory conditions. In a randomized trial, adding methotrexate to prednisone cut the proportion of patients experiencing at least one relapse from about 84% to 45%, and significantly reduced the total steroid dose needed.8PubMed. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial Still, head-to-head comparisons suggest methotrexate does not match tocilizumab’s ability to get patients off steroids quickly.
What Happens When Treatment Stops
This is the critical question for anyone wondering whether GCA can be “cured.” Even patients who achieve full remission on treatment face a meaningful chance of relapse once medication is withdrawn. After stopping tocilizumab, roughly a third of patients relapse within a year, rising to nearly half by 18 months.9Annals of the Rheumatic Diseases. Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis In a separate cohort of patients with large-vessel GCA who stopped all treatment, about 28% relapsed, typically within just two months.10PubMed. Imaging to predict early relapses after treatment discontinuation in patients with large vessel giant cell arteritis – A cohort study
On the brighter side, a retrospective study of biopsy-proven GCA found that around half of patients achieved long-term remission, meaning they were able to stay off therapy without the disease coming back during follow-up.11PubMed. Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study So while relapse is common, it is not inevitable. The difficulty is that there is currently no reliable test to tell which patients are truly “done” with GCA and which are sitting on a smoldering fire that will reignite once the medication blanket is pulled away.
Relapse Patterns and the Value of Early Treatment
Most GCA relapses are relatively minor. In one cohort where about two-thirds of patients relapsed during steroid tapering, the majority of those relapses were classified as minor, often just a rise in blood inflammatory markers without new symptoms.12PubMed Central. Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study Serious complications like new vision loss at relapse were rare in that group. The typical relapse happens when the steroid dose drops to a low level, usually around 5 to 16 milligrams of prednisone, and the response is usually to bump the dose back up, then try tapering again more slowly.
There is growing evidence that how quickly you get treated after symptoms start has a real impact on your chances of staying in remission. A retrospective study found that patients who received early treatment had a relapse rate of 29% during their first steroid taper, compared with 66% among those treated later. That early-treatment advantage held up even after accounting for differences in age, symptoms, and whether patients also received tocilizumab.13Clinical Rheumatology. Impact of early treatment on the relapse-free survival and glucocorticoid dosing in giant cell arteritis: a retrospective cohort study The message is intuitive: the sooner inflammation is suppressed, the less entrenched the immune process becomes in the artery wall, and the easier it is to shut down for good.
Vision Loss and Why Urgency Matters
The most feared complication of GCA is permanent vision loss, which happens when inflammation in the arteries supplying the eye cuts off blood flow to the optic nerve. In a prospective study of 174 patients, visual problems occurred in about 28%, and permanent vision loss in 13%.14PubMed. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients Once it happens, lost vision almost never returns, which is why treatment starts before the diagnosis is confirmed whenever GCA is seriously suspected.
The delay between a patient’s first symptoms and the first medical visit turns out to be a critical window. Patients whose first symptom was visual impairment tended to see a doctor within about two days, but those who started with other symptoms like headache, jaw pain, or scalp tenderness waited a median of three weeks before consulting anyone. In that delay, some went on to develop permanent vision loss that might have been prevented with earlier steroid therapy.15BMJ Open. Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study Distinguishing the arteritic form of optic nerve damage from the more common, non-arteritic form is important because the treatment and prognosis are completely different. A scoring system based on age, inflammatory blood markers, platelet count, and certain eye findings can distinguish the two with high accuracy.16PubMed Central. Clinical, biological, and ophthalmological characteristics differentiating arteritic from non-arteritic anterior ischaemic optic neuropathy
The Aortic Complication That Shows Up Years Later
GCA does not only affect the temporal arteries. It can involve the aorta and its major branches, and this is where the disease carries a long-term risk that persists well beyond the initial treatment period. A population-based study found that GCA patients were about 17 times more likely to develop a thoracic aortic aneurysm than people of the same age and sex without the disease. In that cohort, aneurysms appeared a median of nearly six years after the GCA diagnosis, and six of the eleven patients who developed thoracic aneurysms died of sudden aortic dissection.17PubMed. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study
The mechanism is a gradual weakening of the aortic wall. Chronic inflammation disrupts the structural proteins that give the aorta its strength and elasticity, and the vessel gradually enlarges over time.18PubMed Central. Thoracic Aortic Aneurysm and Giant Cell Arteritis: Clarifying the Link In a follow-up study using CT scans, about 15% of GCA patients showed aortic enlargement or inflammation at diagnosis, and at the six-month mark, only about 9% had complete resolution of their aortic inflammation despite steroid treatment. The rest showed either partial improvement or no change.19Medicine. Long-Term Follow-Up of Aortic Involvement in Giant Cell Arteritis This is one reason many specialists recommend periodic imaging of the aorta in GCA patients for years after diagnosis, even if the cranial symptoms have fully resolved.
Overall Survival and Mortality
GCA does carry a modest impact on life expectancy, though the numbers vary across studies. A large population-based cohort study estimated median survival of about 13 years for GCA patients compared with roughly 14 years for matched controls, with a slightly increased mortality risk concentrated in the first two years after diagnosis and again after ten years.20The Journal of Rheumatology. Mortality among patients with giant-cell arteritis: A large-scale population-based cohort study A smaller, older study from a single center found a more pronounced gap, with five-year survival of 35% in GCA patients versus 67% in controls, though that survival difference converged over time.21PubMed Central. Giant Cell Arteritis and Mortality The discrepancy between these two studies likely reflects differences in cohort size and era of treatment. The larger, more recent study is probably a better reflection of what modern GCA patients can expect. Most people with GCA live for many years after diagnosis, and the disease itself is rarely the direct cause of death outside of aortic complications.
Monitoring Gets Tricky on Certain Therapies
Doctors typically track GCA activity using two blood tests that measure general inflammation: C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR). When these markers rise, it usually signals a flare. The problem is that tocilizumab, by blocking IL-6, directly suppresses the liver’s production of CRP. This means CRP stays low whether the disease is active or not, effectively blinding doctors to one of their main monitoring tools.22Arthritis & Rheumatology. Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab
This masking effect extends beyond disease monitoring. CRP normally rises during bacterial infections, and if it is being suppressed by tocilizumab, infections can be harder to catch early. Researchers have proposed alternative markers to watch for in patients on IL-6 blockers, including procalcitonin (which is produced through a pathway that IL-6 does not control) and the ratio of certain white blood cell types.23PubMed Central. The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature Newer drugs under investigation, such as mavrilimumab (which targets a different immune pathway), may preserve the usefulness of CRP and ESR during treatment, which would be a practical advantage.
Steroid Withdrawal and Adrenal Insufficiency
A problem that gets surprisingly little attention in patient-facing information is what happens to the adrenal glands after months or years of steroid therapy. When you take prednisone for an extended period, your body’s own cortisol production shuts down because the external supply makes it unnecessary. When the prednisone finally stops, the adrenal glands have to wake back up, and that process can take months. In the interim, patients may experience profound fatigue, muscle and joint pain, poor sleep, and a general feeling of being unwell that can mimic a GCA relapse.
A recent study of patients who had stopped prednisolone found that about a third scored in the symptomatic range on a quality-of-life questionnaire designed to detect adrenal insufficiency symptoms. Those patients reported significantly worse fatigue, more musculoskeletal complaints, and poorer sleep quality compared with the group whose adrenal function had recovered.24JAMA Network Open. Changes in Adrenal Function and Insufficiency Symptoms After Cessation of Prednisolone This matters for GCA patients specifically because fatigue and body aches after stopping prednisone can easily be mistaken for a disease flare, leading to unnecessary resumption of steroids. If you are tapering off long-term steroids for GCA, it is worth discussing adrenal function testing with your doctor before assuming that lingering symptoms mean the disease is back.
How GCA Is Diagnosed and Where Ultrasound Fits In
The traditional gold-standard test is a temporal artery biopsy, where a small segment of the artery near the temple is surgically removed and examined under a microscope for signs of inflammation. Biopsy is very specific — if it shows GCA, you can be virtually certain the diagnosis is correct. But its sensitivity is imperfect. In a head-to-head comparison, biopsy picked up about 69% of cases, meaning roughly three in ten people with GCA had a negative biopsy result. Ultrasound of the temporal artery, which looks for a characteristic dark “halo” of swelling around the vessel, had a similar sensitivity of about 63% but lower specificity, meaning it was more prone to false positives.25PubMed Central. Comparison of temporal artery ultrasound versus biopsy in the diagnosis of giant cell arteritis A meta-analysis of 20 studies found the halo sign on ultrasound had pooled sensitivity of 68% and specificity of 81%.26PubMed. Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature
The practical takeaway is that no single test rules out GCA with certainty. A negative biopsy or a clean ultrasound does not mean you are in the clear if the clinical picture is otherwise convincing. Many centers now use ultrasound as an initial screening tool, since it is non-invasive and available the same day, reserving biopsy for cases where ultrasound is inconclusive. But the diagnosis often still rests on the combination of symptoms, blood markers, imaging, and clinical judgment rather than any one test.
The Overlap With Polymyalgia Rheumatica
GCA and polymyalgia rheumatica (PMR) are closely intertwined. PMR, a condition causing widespread aching and stiffness in the shoulders and hips, occurs in about half of patients with temporal arteritis.27PubMed. Temporal arteritis and polymyalgia rheumatica in north-eastern Spain: clinical spectrum and relationship over a 15 year period They share overlapping inflammatory mechanisms involving the same types of immune cells and signaling molecules, and some researchers have proposed that the two conditions belong on a single spectrum rather than being truly separate diseases.28PubMed. Subclinical giant cell arteritis in polymyalgia rheumatica: Concurrent conditions or a common spectrum of inflammatory diseases?
This matters practically because about 7% of patients initially diagnosed with isolated PMR later develop symptoms of temporal arteritis. There were no predictive features in those patients that flagged them as high risk ahead of time. PMR on its own is typically managed with lower doses of steroids and carries less risk of vision loss or aortic complications. But if you have been diagnosed with PMR and develop new headaches, jaw pain, scalp tenderness, or changes in your vision, those symptoms deserve immediate attention because they could signal the emergence of GCA, which requires more aggressive treatment.
Large-Vessel GCA and Why Anatomy Matters
GCA has traditionally been thought of as a disease of the temporal arteries, but imaging studies have shown that many patients also have inflammation in the aorta and its large branches. Patients with predominantly large-vessel disease tend to present differently from those with classic cranial symptoms. They may have more general inflammation, fever, and weight loss rather than headache and jaw claudication. Research has also shown that large-vessel GCA is associated with different immune patterns in the artery wall, including higher levels of certain T-cell signals and a different genetic predisposition profile compared with cranial-predominant disease.29PubMed. Disease pattern in cranial and large-vessel giant cell arteritis These differences hint that GCA is not one uniform disease but a family of related processes that share the common feature of artery-wall inflammation but may differ in which vessels they prefer and how aggressively they cause damage. Patients with large-vessel involvement may need longer-term monitoring even after cranial symptoms resolve, particularly for the aortic complications discussed above.